Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Eisai’s Fycompa Now Available in China
Eisai said on January 6 that it has launched its antiepileptic agent Fycompa (perampanel) in China for use in the adjunctive treatment of partial onset seizures in epilepsy patients. The drug is indicated for the adjunctive treatment of partial onset…
To read the full story
Related Article
- Fycompa Approved for Label Expansion in China: Eisai
May 14, 2024
- Eisai’s Fycompa Gets China Thumbs-Up
October 16, 2019
- Fycompa Designated for Priority Review in China
January 9, 2019
BUSINESS
- FDA Extends Review of Capricor’s DMD Cell Therapy by 3 Months
August 26, 2026
- Leqembi Iqlik Now Available for Alzheimer’s Initiation Use in US
August 25, 2026
- FDA Puts Regenxbio’s MPS II Gene Therapy Back on Clinical Hold
August 25, 2026
- Toho Builds Alternative Drug Delivery Options for Disaster Readiness
August 25, 2026
- OB/GYN Sees Abrysvo Becoming Part of Prenatal Care as NIP Drives Uptake
August 25, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…